CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November.

Details are as follows:

Guggenheim 2nd Annual Healthcare Innovation Conference

Location: Boston, MA

Date: Monday, November 10, 2025

Time: 3:30 PM ET

Webcast Link:

Stifel 2025 Healthcare Conference

Location: New York, NY

Date: Wednesday, November 12, 2025

Time: 4:00 PM ET

Webcast Link:

Jefferies Global Healthcare Conference

Location: London, UK

Date: Thursday, November 20, 2025

Time: 12:00 PM GMT

Webcast Link:

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’  page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Investor Contact

 

Media Contact

Anna Gifford, Chief of Staff

 

617-500-8099



EN
03/11/2025

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming November Investor Even...

Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November. Details are as follows: Guggenheim 2nd Annual Healthcare Innovation ConferenceLocation: Boston, MADate: Monday, November 10, 2025 Time: 3:30 PM ETWebcast Link: ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in Upcoming September Investor Eve...

Compass Therapeutics to Participate in Upcoming September Investor Events BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September. Details are as follows: Citi’s 2025 Biopharma Back to School Conference Location: Boston, MADate: Tuesday, September 2, 2025 Cantor Global Healthcare ConferenceL...

August 26, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Pricing of Upsized $120 Million Public ...

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2...

August 13, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Announces Proposed Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compas...

August 12, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in pat...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch